Form 4: KalVista Pharmaceuticals Executive Christopher Yea Reports Stock Transactions

Christopher Yea, Chief Development Officer of KalVista Pharmaceuticals, reports the acquisition and disposal of company stock, including sales to cover tax obligations related to vesting restricted stock units.

Summary

• Christopher Yea, the Chief Development Officer of KalVista Pharmaceuticals, filed a Form 4 detailing changes in beneficial ownership.
• On August 22, 2024, Yea acquired 3,125 shares of common stock through the vesting of restricted stock units (RSUs).
• On August 23, 2024, Yea sold 1,916 shares at a price of $12.4 per share.
• The sale was to cover tax withholding obligations associated with the vesting of the RSUs.
• Following these transactions, Yea directly owns 85,676 shares of KalVista Pharmaceuticals.
• Yea also holds 46,875 restricted stock units.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing detailing stock transactions by a company executive. It doesn't inherently convey positive or negative sentiment.

Industry Context

Form 4 filings are standard disclosures required by the SEC when company insiders, like officers and directors, trade their company's stock. These filings provide transparency into insider transactions.

Stakeholder Impact

• The transactions may have a minor impact on shareholders as they reflect insider trading activity, but the sale was primarily to cover tax obligations.

Key Dates